Compare L3Harris Technologies Inc (LHX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Tango Therapeutics Inc. — how do they compare? L3Harris Technologies Inc trades at $237.92 (market cap $43.71B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: L3Harris Technologies Inc is far larger — about 11.7× Tango Therapeutics Inc.'s market cap, and L3Harris Technologies Inc pays a 2.13% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and Tango Therapeutics Inc. for 0 Days on average.
| LHX | TNGX | |
|---|---|---|
Market Cap | $43.71B | $3.75B |
Volume | 1,558,148 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $378.48 | $32.90 |
52-Week Low | $233.63 | $7.50 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $54.15B | $2.77B |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $237.50, down 0.31% with a bearish technical signal. The company shows solid fundamentals with consistent earnings beats, revenue growth from $21.3B to $21.9B (2024-2025), and a net income margin improving to 7.34%. Recent news includes a $6B THAAD propulsion contract but also multiple law firm investigations into investor claims, creating mixed sentiment.
Outlook: Strong defense budget tailwinds and recent contract wins support growth, but legal scrutiny and bearish technicals pose near-term risks. Analyst consensus is bullish with a $340 price target (43% upside), highlighting value if legal concerns resolve favorably.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
